GLP1R and Hepatic fibrosis: For example, in a 24-week exploratory phase 2 trial, the GLP-1 receptor agonist semaglutide alleviates cilofexor and firsocostat-induced hypertriglyceridemia, resulting in more significant reductions in liver enzymes, liver fat, and non-invasive imaging assessed liver fibrosis (NCT03987074) (63).